Drug Profile
SLV 339
Alternative Names: SLV339Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Novozymes A/S; Solvay
- Class Pancreatic enzymes
- Mechanism of Action Lipase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pancreatic disorders
Most Recent Events
- 07 Mar 2009 Discontinued - Phase-II for Pancreatic disorders in European Union (PO)
- 03 Oct 2006 Phase-I clinical trials in Pancreatic disorders in European Union (unspecified route)
- 03 Oct 2006 SLV 339 received Orphan Drug status for Pancreatic disorders in the European Union